Results 191 to 200 of about 32,347 (265)

Nootkatone antifungal activity and calcium signaling-mediated resistance in Aspergillus fumigatus. [PDF]

open access: yesAppl Microbiol Biotechnol
Xu J   +7 more
europepmc   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

open access: yesAllergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian   +18 more
wiley   +1 more source

Agonist‐specific conformational dynamics at the β2‐adrenoceptor dictate allosteric modulation of Gαs signalling and bronchodilation

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose β2‐adrenoceptor (β2AR) agonists are the cornerstone of asthma therapy and promote bronchodilation through Gαs signalling in airway smooth muscle (ASM), but their efficacy is limited by β‐arrestin‐mediated β2AR desensitization.
Sushrut D. Shah   +7 more
wiley   +1 more source

Dental Pulp Stem Cell‐Derived Intracellular Vesicles Inhibit OSCC by Delivering PTEN to Suppress PI3K/AKT/mTOR Signalling Pathway

open access: yesCell Proliferation, EarlyView.
DPSC‐IVs suppressed PI3K/AKT/mTOR signalling pathway by delivering PTEN to tumour cells, which reduced the expression of Bcl‐2 and elevated that of Bax. Meanwhile, DPSC‐IVs activated PINK1/Parkin mediated mitophagy, which further raised ROS levels.
Yu Luo   +10 more
wiley   +1 more source

Biocide Response of Candida auris. [PDF]

open access: yesMycoses
Erganis S   +3 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy